Back to Search
Start Over
Ruxolitinib: Targeted Approach for Treatment of Autoinflammatory Very Early Onset Inflammatory Bowel Disease.
- Source :
- Clinical Gastroenterology & Hepatology; Jun2022, Vol. 20 Issue 6, p1408-1408, 1p
- Publication Year :
- 2022
-
Abstract
- Very early onset inflammatory bowel disease (VEO-IBD), diagnosed <6 years old, can be genetically and phenotypically distinct and more refractory than older-onset IBD. Identified causal monogenic defects have been targeted therapeutically in a small subset of VEO-IBD<superscript>1</superscript>; however, for most of these children, treatment strategies, such as phenotypic profiles, are critically needed to improve outcomes. [ABSTRACT FROM AUTHOR]
Details
- Language :
- English
- ISSN :
- 15423565
- Volume :
- 20
- Issue :
- 6
- Database :
- Supplemental Index
- Journal :
- Clinical Gastroenterology & Hepatology
- Publication Type :
- Academic Journal
- Accession number :
- 156648977
- Full Text :
- https://doi.org/10.1016/j.cgh.2021.07.040